Medicines · 3 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review examines the potential of collagen hydrolysates (CHs) and their bioactive peptides (BAPs) for treating osteoarthritis. It summarizes evidence from human clinical trials showing benefits for joint pain and mobility, alongside preclinical studies on bone and cartilage health, while highlighting key gaps in knowledge about digestion, bioavailability, and mechanisms.
This narrative review synthesizes evidence on collagen hydrolysates (CHs) for osteoarthritis (OA) treatment. It notes that clinical trials have shown CHs are associated with decreased joint pain, increased mobility, and structural joint improvements. The review details preclinical evidence: animal and in vitro studies suggest CHs and specific peptides like Pro-Hyp can inhibit chondrocyte loss, promote osteoblast differentiation, and increase bone mineral density. The discussion covers critical limitations, including knowledge gaps in CH digestion, bioavailability, and the precise mechanisms of bioactive peptides. The authors conclude that while CHs show promise, further transparent, mechanistic research is needed to establish their efficacy and optimal use.
